Maxwellia announces three new board appointments to strengthen commercial and strategic leadership

Alderley Park, Cheshire, UK – Tuesday 29 July 2025 – Maxwellia is pleased to announce the appointments of Candice Brett as an Executive Director and Ian Adamson and John Gunn as Non-Executive Directors to the Maxwellia Board. The appointments form part of Maxwellia’s ongoing commitment to building a high-performing leadership team that supports the company’s mission to make more medicines available without prescription and empower more people to take control of their health.

​Each new Board member brings deep expertise from across the healthcare and investment landscape, strengthening Maxwellia’s strategic capabilities as the business continues to scale.

Candice Brett, Maxwellia’s Chief Financial Officer, brings a wealth of financial and strategic leadership experience to Maxwellia’s board. With a strong track record across a range of industries, including recent senior roles at Faith in Nature, THG and HMG Paints.

Ian Adamson has been supporting Maxwellia as a Strategic Advisor for several years and has now formally joined Maxwellia’s board, bringing over 30 years of global experience in consumer health and personal care. His extensive industry insight and commercial acumen will support Maxwellia as it builds on recent regulatory milestones and continues to expand access to pharmacy medicines. Ian’s background advising major healthcare businesses and leading household-name brands will be an asset as the company enters its next phase of growth.

John Gunn is a seasoned investor and business leader with deep expertise across financial services, investment, and corporate strategy. With a strong background in M&A, IPOs and corporate governance, John’s insight will be instrumental in guiding Maxwellia’s long-term growth and value creation as the company scales its operations.

Maxwellia Founder and CEO, Anna Maxwell says: “We’re thrilled to welcome Candice, Ian and John to the Maxwellia Board. Each of them brings unique strengths and proven expertise that will help us accelerate our mission to democratize access to medicines. Their leadership and insight will be invaluable as we continue to grow, innovate and transform the way people access the care they need.”